Bookmark and Share

Compound Summary for: CID 387447     Try the new version summary page


Also known as: Velcade; 179324-69-7; PS-341; Ps 341; DPBA; LDP-341; Peptide boronate; CHEBI:52717; PS341
Molecular Formula: C19H25BN4O4   Molecular Weight: 384.2372   InChIKey: GXJABQQUPOEUTA-RDJZCZTQSA-N
Bortezomib (originally PS-341 and marketed as Velcade by Millennium Pharmaceuticals) is the first therapeutic proteasome inhibitor to be tested in humans. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma. In multiple myeloma, complete clinical responses have been obtained in patients with otherwise refractory or rapidly advancing disease.   From: DrugBank
Show subcontent titlesTable of Contents
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Biomedical Effects and Toxicity
Safety and Handling
Environmental Fate and Exposure Potential
Exposure Standards and Regulations
Biomolecular Interactions and Pathways
Biological Test Results
Chemical and Physical Properties
_ _